Brought to you by 
Syndax raises $26.6mm through Series B round
27 Sep 2013
Executive Summary
Syndax Pharmaceuticals Inc. (epigenetics-based cancer therapies) raised $26.6mm through its Series B round. Returning backers Domain Associates, MPM Capital, and Forward Ventures were joined by new investors RusnanoMedInvest. Some of the proceeds will fund an NDA-enabling Phase III trial of the HDAC inhibitor entinostat for metastatic breast cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syndax raises $26.6mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice